SLRN vs. PHVS, CRMD, AKBA, OCS, LENZ, PRAX, ZYME, CMRX, CDMO, and NUVB
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Pharvaris (PHVS), CorMedix (CRMD), Akebia Therapeutics (AKBA), Oculis (OCS), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.
Acelyrin vs.
Acelyrin (NASDAQ:SLRN) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
87.3% of Acelyrin shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Pharvaris had 14 more articles in the media than Acelyrin. MarketBeat recorded 14 mentions for Pharvaris and 0 mentions for Acelyrin. Pharvaris' average media sentiment score of 0.63 beat Acelyrin's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.
Pharvaris' return on equity of -38.52% beat Acelyrin's return on equity.
Acelyrin presently has a consensus price target of $9.60, suggesting a potential upside of 322.91%. Pharvaris has a consensus price target of $37.25, suggesting a potential upside of 110.69%. Given Acelyrin's higher possible upside, analysts plainly believe Acelyrin is more favorable than Pharvaris.
Acelyrin has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.86, indicating that its share price is 386% less volatile than the S&P 500.
Pharvaris received 23 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 67.24% of users gave Pharvaris an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.
Pharvaris is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Summary
Pharvaris beats Acelyrin on 9 of the 15 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
This page (NASDAQ:SLRN) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy SLRN Stock Free SLRN Stock Alerts